Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Presidential Symposium I

5638 - PACIFIC: A double-blind, placebo-controlled Phase III study of durvalumab after chemoradiation therapy (CRT) in patients with Stage III, locally advanced, unresectable NSCLC

Date

09 Sep 2017

Session

Presidential Symposium I

Topics

Immunotherapy;  Non-Small Cell Lung Cancer

Presenters

Luis Paz-Ares

Citation

Annals of Oncology (2017) 28 (suppl_5): v605-v649. 10.1093/annonc/mdx440

Authors

L. Paz-Ares1, A. Villegas2, D. Daniel3, D.V. Baz4, S. Murakami5, R. Hui6, T. Yokoi7, A. Chiappori8, K.H. Lee9, M. de Wit10, B.C. Cho11, M. Bourhaba12, X. Quantin13, T. Tokito14, T. Mekhail15, D. Planchard16, H. Jiang17, Y. Huang17, P.A. Dennis17, M. Özgüroğlu18

Author affiliations

  • 1 Medical Oncology, Hospital Universitario 12 de Octubre, CiberOnc, Universidad Complutense and CNIO, 28041 - Madrid/ES
  • 2 Medical Oncology, Cancer Specialists of North Florida, Jacksonville/US
  • 3 Sarah Cannon Research Institute, Tennessee Oncology, Chattanooga/US
  • 4 Medical Oncology, Hospital Universitario Virgen Macarena, Seville/ES
  • 5 Thoracic Oncology, Kanagawa Cancer Center, Yokohama/JP
  • 6 Medical Oncology, Westmead Hospital and the University of Sydney, Sydney/AU
  • 7 Thoracic Oncology, Kansai Medical University Hospital, Hirakata/JP
  • 8 Medical Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa/US
  • 9 Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju/KR
  • 10 Hematology And Oncology, Vivantes Klinikum Neukoelln, Berlin/DE
  • 11 Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul/KR
  • 12 Medical Oncology, Centre Hospitalier Universitaire de Liège, Liège/BE
  • 13 Medical Oncology, CHU Montpellier and ICM Val d'Aurelle, Montpellier/FR
  • 14 Internal Medicine, Kurume University Hospital, Kurume/JP
  • 15 Hematology And Medical Oncology, Florida Hospital Cancer Institute, Orlando/US
  • 16 Medical Oncology, Gustave Roussy, Villejuif/FR
  • 17 Immuno-oncology, AstraZeneca, Gaithersburg/US
  • 18 Internal Medicine, Istanbul University Cerrahpasa School of Medicine, Istanbul/TR
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5638

Background

Most patients (pts) with locally advanced, unresectable non-small cell lung cancer (NSCLC) progress despite concurrent chemoradiation therapy (cCRT). Here we report interim results from a global, Phase 3 study (NCT02125461) of the anti-PD-L1 durvalumab as consolidation therapy in Stage III pts without progression following platinum-based cCRT.

Methods

Pts with a WHO performance status 0/1 (any PD-L1 status) who received ≥2 cycles of platinum-based cCRT without progression were randomized (2:1) 1–42 days post-cCRT to receive durvalumab 10 mg/kg IV Q2W or placebo for up to 12 months, stratified by age, sex, and smoking history. Co-primary endpoints were progression-free survival (PFS; blinded independent central review, RECIST v1.1) and overall survival (OS). Secondary endpoints included 12- and 18-month PFS rates, objective response rate (ORR), duration of response (DoR), time to death or distant metastasis (TTDM) and safety.

Results

Between May 2014 and April 2016, 713 pts were randomized of whom 709 received consolidated treatment (durvalumab, n = 473; placebo, n = 236). Baseline characteristics were well balanced. As of Feb 13, 2017 (data cutoff), median follow-up was 14.5 months. Median PFS from randomization was significantly longer with durvalumab (16.8 months, 95% CI, 13.0–18.1) versus placebo (5.6 months, 95% CI, 4.6–7.8; stratified HR 0.52, 95% CI, 0.42–0.65; P 

Conclusions

Durvalumab demonstrated significant and clinically meaningful improvement in PFS, which was supported by secondary endpoints, and was well tolerated. Durvalumab is a promising therapeutic option in this setting.

(Dr. Scott J. Antonia of H. Lee Moffitt Cancer Center and Research Institute is the lead author for this study. Dr. Luis Paz-Ares is presenting on his behalf).

Clinical trial identification

NCT02125461 (April 25, 2014)

Legal entity responsible for the study

AstraZeneca

Funding

AstraZeneca

Disclosure

L. Paz-Ares: Consultancy fees from AstraZeneca, Bristol-Myers Squibb, Merck Sharp and Dohme, Pfizer, Roche, Lilly, Boehringer Ingelheim, Novartis, and Ariad. A. Villegas: Speaker honoraria from Celgene, Alexion, and Bristol-Myers Squibb. R. Hui: Advisory board fees from AstraZeneca, Merck Sharp and Dohme, and Novartis, and a speaker honorarium from Merck Sharp and Dohme. A. Chiappori: Speaker honoraria from Genentech, Merck, Takeda, Novartis, Pfizer, Boehringer Ingelheim, and Celgene, and research support from Novartis and Bristol-Myers Squibb. M. de Wit: A speaker honorarium from AstraZeneca. T. Mekhail: A speaker honorarium and research support from AstraZeneca. D. Planchard: Advisory board fees from AstraZeneca, Bristol-Myers Squibb, Merck Sharp and Dohme, Pfizer, Novartis, Roche, Lilly, and Boehringer Ingelheim. H. Jiang, Y. Huang, P.A. Dennis: Full-time employee of AstraZeneca with stock ownership. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.